Compare CCTG & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCTG | GDTC |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | Hong Kong | Singapore |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 10.4M |
| IPO Year | 2022 | 2021 |
| Metric | CCTG | GDTC |
|---|---|---|
| Price | $0.61 | $0.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 97.5K | 18.5K |
| Earning Date | 12-23-2025 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $0.68 |
| 52 Week High | $5.64 | $3.68 |
| Indicator | CCTG | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 39.88 |
| Support Level | $0.38 | $0.73 |
| Resistance Level | $0.65 | $1.08 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 15.47 | 13.91 |
CCSC Technology International Holdings Ltd, through its direct wholly-owned subsidiaries, is principally engaged in the manufacturing and sale of interconnect products, including connectors, cables and wire harnesses. The company produces both original equipment manufacturer (OEM) and original design manufacturer (ODM) interconnect products for manufacturing companies that produce end products, as well as for electronic manufacturing services (EMS) companies. The majority of the company's revenue is derived from the sale of Cable and wire harnesses, and Connectors. Geographically, the company generates maximum revenue from the sale of its products in Europe and the rest from the Americas, Asia, and Others.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.